When One Antidepressant Isn't Enough: A Guide to Augmentation Strategies
Written by Vaishali Desai, PMHNP-BC
If your first antidepressant didn't fully work, you are not failing treatment — you are encountering the statistical reality of depression pharmacology. The landmark STAR*D study found that only one-third of patients achieved remission on their first antidepressant. The rest needed a second, third, or more complex strategy — and augmentation is one of the most important tools in that toolkit.
Augmentation means adding a second medication to an antidepressant that is producing a partial but incomplete response. It is not the same as switching — and knowing which situation calls for which approach is one of the key clinical decisions in depression management. This guide explains the evidence, the mechanisms, and what each augmentation strategy is actually doing.
Disclaimer: This article is for educational purposes only and does not constitute medical advice or a provider-patient relationship. Always consult your licensed healthcare provider before making changes to any treatment plan.
Augmentation vs. Switching: When to Do Each
The decision between augmentation and switching depends on the pattern of response — or non-response — to the current antidepressant:
- Augment when the current antidepressant is producing a partial response — meaningful improvement in some symptoms, but not remission. Adding an augmenting agent to an already-partially-working medication preserves that partial gain while addressing residual symptoms through a complementary mechanism.
- Switch when the antidepressant is producing no meaningful response after an adequate trial (typically 4–8 weeks at therapeutic dose). In the absence of any response, there is no partial gain to preserve, and a different mechanism may be needed.
- Switch when the patient has intolerable side effects — augmenting a medication the patient cannot tolerate is not clinically useful, and the right move is to replace it.
Clinical Note: “Adequate trial” matters here. An antidepressant that was only tried for 2 weeks at half-dose is not a trial — it is a start. Before concluding that an antidepressant has failed, confirm that the patient was on a therapeutic dose for 4–8 weeks. Premature switching is one of the most common reasons patients accumulate antidepressant “failures” that weren't actually failures.
Why Partial Response Is So Common
Depression is not a single biological entity. It is a heterogeneous syndrome — the same symptom cluster can arise from multiple distinct underlying mechanisms, and a given patient may have multiple contributing factors simultaneously:
- Serotonin system saturation — SSRIs primarily work by blocking serotonin reuptake (SERT inhibition). Once serotonergic neurotransmission is maximally enhanced, further dose increases produce diminishing returns — and the remaining symptoms may be driven by non-serotonergic mechanisms.
- Receptor downregulation — chronic SSRI use causes downregulation of certain serotonin receptors (5-HT2A, 5-HT2C), which can blunt the therapeutic signal over time — the mechanism behind some “poop-out” phenomena in long-term antidepressant use.
- Inflammatory mechanisms — elevated pro-inflammatory cytokines (IL-6, TNF-alpha, CRP) are present in a meaningful subset of depression and are not directly addressed by SSRI/SNRI mechanisms. This is why some “inflammatory depression” subtypes respond better to anti-inflammatory augmentation than to serotonin modulation alone.
- Glutamatergic mechanisms — the glutamate/NMDA system plays a major role in synaptic plasticity and depression that monoaminergic antidepressants do not address — the mechanism behind ketamine's rapid efficacy.
Evidence-Based Augmentation Options
Atypical Antipsychotics
Agents: aripiprazole (Abilify), quetiapine (Seroquel XR), olanzapine (Symbyax when combined with fluoxetine), brexpiprazole (Rexulti)
Mechanism: D2 partial agonism + 5-HT2A antagonism. By blocking 5-HT2A receptors, these agents disinhibit dopamine and norepinephrine release in the prefrontal cortex — complementing the serotonergic enhancement of the underlying antidepressant through a different pathway.
Evidence: Aripiprazole, quetiapine XR, and brexpiprazole all carry FDA approval for MDD augmentation — the strongest regulatory endorsement of any augmentation class.
Monitoring: Metabolic effects are a real concern — weight, fasting glucose, lipids, waist circumference, and blood pressure should be tracked at baseline, 3 months, and then annually. Quetiapine and olanzapine carry the highest metabolic burden; aripiprazole and brexpiprazole are more metabolically neutral.
Lithium
Mechanism: Lithium enhances serotonergic neurotransmission through multiple pathways, including increasing serotonin synthesis and release, and modulating postsynaptic serotonin receptor sensitivity. It may also have direct neuroprotective effects through BDNF upregulation and GSK-3 inhibition.
Evidence: Lithium is the original antidepressant augmentation agent — the evidence base dates to the 1980s. Multiple meta-analyses confirm its efficacy. It remains effective but is underused in clinical practice due to monitoring burden.
Monitoring: Narrow therapeutic index (0.6–1.0 mEq/L for augmentation). Requires baseline and ongoing monitoring of serum lithium level, renal function (BMP), and thyroid function (TSH). Patients need to understand dehydration risk and drug interactions.
Buspirone
Mechanism: 5-HT1A partial agonism — autoreceptor stimulation initially reduces serotonergic firing, but chronic use leads to autoreceptor desensitization and net increase in serotonergic transmission. Also has modest D2 effects.
Best for: Augmentation when co-occurring anxiety is prominent, or when a low-side-effect-burden option is preferred. Well tolerated; no metabolic monitoring required; no dependence risk.
Important caveat: Buspirone requires 2–4 weeks to produce meaningful effect — much longer than benzodiazepines. The most common reason for dropout is patients concluding it “doesn't work” before the 2–4 week window has elapsed. Setting clear expectations is essential.
Mirtazapine (NaSSA)
Mechanism: Noradrenergic and specific serotonergic antidepressant (NaSSA). Presynaptic alpha-2 adrenoreceptor blockade increases norepinephrine and serotonin release; 5-HT2A/2C and 5-HT3 antagonism improves tolerability and contributes to antidepressant effect. H1 antagonism produces sedation and appetite stimulation.
California Rocket Fuel: The combination of venlafaxine + mirtazapine has a strong evidence base in treatment-resistant depression. The combination is sometimes called “California Rocket Fuel” — venlafaxine's SNRI mechanism + mirtazapine's NaSSA mechanism produces broad monoaminergic coverage with complementary pharmacology.
Best for: Patients with insomnia, poor appetite, or nausea as prominent residual symptoms. Sedation can be dose-dependent and paradoxically less prominent at higher doses.
Thyroid (T3 / Liothyronine)
Mechanism: T3 augments antidepressant response through enhanced noradrenergic sensitivity — increasing the density and sensitivity of beta-adrenergic receptors in the brain, which potentiates the noradrenergic component of antidepressant action.
Best for: Patients with subclinical hypothyroidism or those at the lower end of the normal thyroid range. Even in euthyroid patients, T3 augmentation has shown benefit in RCTs. Monitor thyroid function during use.
Bupropion (NDRI)
Mechanism: Norepinephrine-dopamine reuptake inhibitor (NDRI) plus partial nicotinic acetylcholine receptor agonist. Adding bupropion to an SSRI or SNRI introduces a dopaminergic-noradrenergic component to complement the serotonergic foundation.
Best for: Residual fatigue, concentration difficulties, and motivational impairment after an SSRI has addressed mood and anxiety. Also useful when SSRI-induced sexual dysfunction is present (bupropion does not cause sexual dysfunction and may improve it).
Caution: Lowers seizure threshold at higher doses; avoid in patients with seizure history, active eating disorders (electrolyte disruption → seizure risk), or heavy alcohol use. CYP2D6 inhibition can increase levels of co-administered medications.
Lamotrigine
Mechanism: Voltage-gated sodium channel blockade → reduced glutamate release → glutamatergic modulation in limbic and cortical circuits. Addresses the glutamatergic mechanisms that monoaminergic antidepressants do not.
Best for: Bipolar depression (first-line; FDA-approved for bipolar maintenance) and treatment-resistant unipolar depression, particularly when the mood profile suggests a softer bipolar spectrum. Also useful when depression features emotional blunting or cognitive symptoms.
Critical note: Requires slow titration due to Stevens-Johnson Syndrome (SJS) risk — typically 25mg/day for 2 weeks, then 50mg for 2 weeks, titrating up by 25–50mg every 2 weeks. SJS risk is dramatically increased with rapid titration or combination with valproate.
Written by a PMHNP-BC
Medication Management for Depression
A clinical guide to antidepressants, augmentation, and treatment-resistant depression — what's happening in the brain, the evidence behind each option, and how to have an informed conversation with your prescriber. Written by Vaishali Desai, PMHNP-BC.
⚡ Instant download — available immediately after purchase
Ketamine and Esketamine (Spravato)
Ketamine and its S-enantiomer esketamine (Spravato) work through a fundamentally different mechanism than all other augmentation agents: NMDA receptor antagonism → rapid downstream glutamatergic signaling changes → rapid synaptogenesis via BDNF/AMPA receptor upregulation. The result is antidepressant effect within hours to days, compared to the weeks required by monoaminergic agents.
Esketamine (Spravato) is FDA-approved for:
- Treatment-resistant depression (TRD) — inadequate response to two or more adequate antidepressant trials
- MDD with acute suicidal ideation or behavior (MDSI)
Clinical realities: Spravato is administered in a certified healthcare setting (patients must be observed for 2 hours after each dose due to dissociation and sedation risk); it is not available for home use. Response rates are meaningful but not universal, and esketamine alone without an accompanying oral antidepressant does not appear to maintain remission long-term. It is best understood as a rapid-acting intervention to bridge the patient to sustained antidepressant response — not a standalone long-term strategy.
TMS and ECT: Non-Pharmacological Augmentation
Non-pharmacological interventions are not separate from augmentation — they are augmentation options for patients who have not achieved adequate response with medications:
- TMS (Transcranial Magnetic Stimulation) — FDA-approved for TRD; repetitive magnetic pulses to the left dorsolateral prefrontal cortex (rTMS) or theta-burst protocols. Non-invasive; typically 20–36 sessions over 4–6 weeks; response rate ~50–60% in TRD. Can be combined with ongoing antidepressants.
- ECT (Electroconvulsive Therapy) — the most effective intervention available for severe or treatment-resistant depression, with remission rates of 60–80% in TRD; also first-line for acute suicidality, catatonia, and severe psychotic depression. Often used when pharmacological augmentation has failed. Cognitive side effects (particularly retrograde amnesia) are the major limitation and vary by electrode placement.
Referral for TMS or ECT evaluation is appropriate after two or more adequate antidepressant trials with augmentation have failed to produce remission — or earlier in the presence of active suicidality or severe functional impairment.
The STAR*D Reality: Augmentation Is the Norm
The STAR*D (Sequenced Treatment Alternatives to Relieve Depression) study is the largest antidepressant effectiveness trial ever conducted — and its findings reframe what patients and clinicians should expect from depression treatment:
- Step 1: ~33% remission rate on first antidepressant (citalopram)
- Step 2: ~25–30% remission with second-step augmentation or switch
- Step 3: ~15–20% remission in those who hadn't responded to two prior steps
The clinical message: needing augmentation is not a sign of a treatment failure or unusual severity. It is the expected trajectory for the majority of people with depression. The appropriate response is a systematic, stepped approach — not escalating concern or feelings of hopelessness about treatment.
Monitoring Requirements by Augmentation Agent
Different augmentation agents have different monitoring needs. A general overview:
| Agent | What to Monitor | When |
|---|---|---|
| Atypical antipsychotics | Weight, fasting glucose, lipids, BP, waist circumference | Baseline, 3 mo, then annually |
| Lithium | Serum lithium level, BMP (renal), TSH | Baseline, 5–7 days after dose changes, then q3–6 mo |
| T3 | TSH, free T4, heart rate, bone density (long-term) | Baseline and periodically during use |
| Lamotrigine | Rash surveillance (SJS risk); valproate interaction | Ongoing during titration; no blood levels needed unless seizure disorder |
| Buspirone, bupropion, mirtazapine | No specific monitoring; symptom response and side effects | Clinical check-ins |
Prescriber's Note
Staging treatment resistance helps calibrate the clinical response. A commonly used framework:
- Stage I: Failure of one adequate trial (adequate dose × adequate duration, typically 4–8 weeks)
- Stage II: Failure of two adequate trials
- Stage III: Failure of two adequate trials + one augmentation strategy
- Stage IV+: Multiple failed strategies — referral to psychiatry strongly indicated
When to refer augmentation to psychiatry rather than managing in primary care: Stage III and above; complex polypharmacy; bipolar spectrum concerns; when lithium, lamotrigine, or antipsychotics are being considered and the prescriber is less comfortable with those agents' monitoring requirements; or when safety concerns are present.
Documentation of adequate dose and duration before calling a trial failed is both clinically important and medicolegally relevant. Document the starting dose, titration steps, maximum dose reached, duration at maximum dose, and reason for discontinuation.
Vaishali Desai, PMHNP-BC is a Board-Certified Psychiatric Mental Health Nurse Practitioner with nearly 10 years of clinical experience in mental health. She is the founder of 360 Mental Healing LLC and 360 Mind Shop, created to give patients and families the clinical information they deserve in language they can actually use.
This article is for educational and informational purposes only. It does not constitute medical advice, a clinical assessment, or a provider-patient relationship. Always consult your licensed healthcare provider before starting, stopping, or changing any medication or treatment plan. If you are experiencing a psychiatric emergency, call or text 988 or go to your nearest emergency room.
Go Deeper on Depression and Medication Management
Two clinician-written guides — one on managing depression medications, one on starting psychiatric medication — both from Vaishali Desai, PMHNP-BC.